ABBVAbbVieSigning up patients
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 660 (planned)
- Started
- Jun 30, 2026
- Main results expected
- Jun 2032
- Fully finished
- Jun 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 2: Complete remission (CR)
Measured over: Up to Approximately 71 Months
Phase 3: Complete remission (CR)
Measured over: Up to Approximately 71 Months
Phase 3: Overall Survival (OS)
Measured over: Up to Approximately 71 Months
Number of Participants with Adverse Events (AEs)
Measured over: Up to approximately 71 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07581002 · record last updated 2026-10-22 · checked 2026-11-09 15:47 UTC